

Page ranges in **bold** refer to Dr. Ro's Pearls of Wisdom.

A

- A1C levels, 35, 79
- access points
- for hemodialysis, 139, 152, 154, 155, 156–159
 - for peritoneal dialysis, 149, 150, 151
- ACE (angiotensin-converting enzyme) inhibitors
- for glomerular disease, 69
 - for high blood pressure, 72
 - precautions when using, 81, 101, 106
 - for proteinuria, 69, 72, 73–74
 - temporary eGFR drops caused by, 58–60, 62–63, 74–75
- acetaminophen (Tylenol), 81, 82
- acidosis, 96–98, 120–121
- activated vitamin D (calcitriol), 117, 119, 120
- acute kidney injury (AKI). *See* reversible kidney function declines
- acute tubular necrosis (ATN), 55, 56–58
- Adderall, 72
- adult-onset diabetes (type 2), 66. *See also* diabetes
- advanced chronic kidney disease
- anemias and, 111–115, 121–122, **176–177**. *See also* anemias
 - defined, 85
 - electrolyte management for, 95–110, **174–176**. *See also* electrolyte management
 - mineral and bone diseases related to, 115–122, **177–178**. *See also* chronic kidney disease mineral and bone disorder
 - NSAIDs precautions for, 81–82
 - renal replacement therapy options, 123. *See also* dialysis; kidney transplant
 - Smart Diet modifications for, 51–52
- Advil (ibuprofen), 58, 81–82. *See also* NSAIDs
- African Americans, 68
- age, rate of kidney function decline and, 88–89. *See also* older adults
- AKI (acute kidney injury). *See* reversible kidney function declines
- albumin, 17, 97
- albuminuria, 17, 20, 21
- Aldactone (spironolactone), 100. *See also* potassium-sparing diuretics
- Aleve, 58. *See also* NSAIDs
- Aleve (naproxen), 82. *See also* NSAIDs
- alkali therapy, 79–80
- alkalosis, 96
- amiloride (Midamor), 100. *See also* potassium-sparing diuretics
- anemias, 111–115
- about, 111
 - causes, 112–113
 - diagnosing, 113
 - summary, 121–122, **176–177**
 - symptoms, 114
 - treatment, 114–115
- angiotensin-converting enzyme inhibitors. *See* ACE inhibitors
- antacids, 60, 114, 117. *See also* calcium-containing phosphorus binders
- A1C levels, 35, 79
- ARBs (angiotensin-receptor blockers)
- for glomerular disease, 69
 - for high blood pressure, 72
 - precautions when using, 81, 101, 106
 - for proteinuria, 69, 72, 73–74
 - reversible kidney function declines caused by, 58–60, 62–63, 74–75
- aristolochic acid, 3, 53
- arterial calcification, 116, 117
- aspirin, 81, 82, 83
- atherosclerosis, 25–37
- about, 25–26
 - as cause of kidney disease, 68
 - lifestyle changes for avoiding, 2–3, 26–36, 40, 46–47
 - management of, 73–74
 - metabolic acidosis and, 97
 - risk factors, 2–3, 20–21, 27–34, 36, 46–47, 66
 - Smart Diet and, 2, 40, 46
 - summary, 37, **166–167**
 - symptoms, 26
- ATN (acute tubular necrosis), 55, 56–58
- atorvastatin (Lipitor), 34
- AV (arteriovenous) access, 139, 152, 154, 155, 156–159
- AV (arteriovenous) fistula, 139, 154, 156–158, 159
- azilsartan, 59, 101. *See also* ARBs

B

- baby aspirin, 83
- Bactrim (sulfamethoxazole and trimethoprim), 101
- “bad” cholesterol (LDL), 29, 33–34, 45, 46

- baking soda (sodium bicarbonate), 3, 79–80, 97–98, 101, 121
- benazepril, 59, 101. *See also* ACE inhibitors
- benign prostatic hypertrophy, 63
- beverages
- alcoholic, 44, 72
 - caffeinated, 44
 - sugary, 43, 51
- bicarbonate levels, 95–96, 97–98, 120
- bladder, 11, 63–64
- bleeding, CKD-related, 136
- blood, in urine, 16, 17–20
- blood creatinine. *See* serum creatinine
- blood pH, 12, 96, 98
- blood pressure. *See also* high blood pressure; low blood pressure
- protocol for accurate readings, 31
 - target blood pressures, 31–32, 70–71
- blood pressure medications, 30–32, 57, 58–60, 71–72. *See also* ACE inhibitors; ARBs
- blood sugar control, 35–36, 45, 66–67, 78–79, 97
- blood transfusions, 112, 115, 147
- bone disorders. *See* chronic kidney disease mineral and bone disorder
- Buchwald, Art, 57
- bumetanide (Bumex), 107. *See also* loop diuretics
- C**
- caffeinated beverages, 44
- calcified blood vessels, 116, 117
- calcimimetics, 119
- calcitriol (Rocaltrol or activated vitamin D), 117, 119, 120
- calcium-containing phosphorus binders (antacids), 60, 114, 117, 119
- calcium levels, 12, 95–96, 115–116, 119, 120
- calorie intake, 34, 40, 41–45
- canagliflozin, 67
- candesartan, 59, 101. *See also* ARBs
- canned foods, 51, 102
- CAPD (continuous ambulatory peritoneal dialysis), 149
- captopril, 59. *See also* ACE inhibitors
- carbohydrate intake, 41, 43–46
- carbon dioxide, 96, 97
- causes, of CKD, 66–72
- atherosclerosis, 68. *See also* atherosclerosis
 - diabetic kidney disease, 66–67. *See also* diabetes
 - glomerular diseases, 68–69
 - hypertensive nephropathy, 67–68. *See also* high blood pressure
 - polycystic kidney disease, 69–70
- CBC (complete blood count), 113
- Celebrex, 58. *See also* NSAIDs
- central venous catheter (CVC access), 154, 158, 159
- CHF. *See* congestive heart failure
- Chinese herbs, 3
- chloride levels, 95, 98
- chlorthalidone (Diuril), 107. *See also* thiazide diuretics
- cholesterol levels, 29, 33–34, 45, 46
- chronic kidney disease (CKD)
- associated disorders, 111–122. *See also* anemias; atherosclerosis; chronic kidney disease mineral and bone disorder; diabetes
 - causes of, 66–72. *See also* causes, of CKD
 - diagnosis, 13, 23. *See also* estimated glomerular filtration rate; glomerular filtration rate
 - management of, 65–84, 139–161. *See also* dialysis; kidney transplant; management, of CKD
 - myths about, 19
 - overdiagnosis of, 19
 - prevalence, 1
 - prognosis, 3–4. *See also* kidney function declines
 - stages of, 18–23. *See also* stages, of chronic kidney disease
 - symptoms, lack of, 4, 19
- chronic kidney disease mineral and bone disorder (CKD-MBD), 115–121
- about, 115–116
 - fracture rates and, 120
 - metabolic acidosis and, 120–121
 - protein intake and, 47–48
 - summary, 121–122, **177–178**
 - treatment recommendations, 117–120
- cinacalcet hydrochloride (Sensipar), 119. *See also* vitamin D drugs
- CKD. *See* chronic kidney disease
- CKD-MBD. *See* chronic kidney disease mineral and bone disorder
- Clark, W., 80
- complete blood count (CBC), 113

congestive heart failure (CHF)
 anemia and, 114
 early start of dialysis due to, 132, 135
 hemodialysis and, 153
 management of, 106
 patient example, 109
 precautions for, 79–80, 81, 97–98, 100
 reversible kidney function declines and, 62–63
continuous ambulatory peritoneal dialysis (CAPD), 149
creatinine. *See* serum creatinine; urine
creatinine clearance, 14–15, 80, 130–131
CVC access (central venous catheter), 154, 158, 159

D

dapagliflozin, 67
dehydration, 56–57, 58, 61, 80–81
diabetes
 atherosclerosis risk and, 36, 66
 bladder-emptying problems, 64
 blood sugar control for, 3, 35–36, 79
 cholesterol level goals for, 33–34, 46
 diabetic kidney disease (nephropathy), 66–67, 68, 79
 diabetic retinopathy, 35, 36, 66–67
 dialysis guidelines for, 134
 diet recommendations, 39, 44, 45, 75–76
 eye exams for, 36
 foot care for, 36
 glomerular disease and, 69
 hyperkalemia and, 99
 prevention, 34, 44, 45
 type 1 and type 2, 66
diabetic kidney disease (nephropathy), 66–67, 68, 79
diabetic retinopathy, 35, 36, 66–67
dialysis
 about, 87, 125–126, 139–140
 for acute kidney injury, 55, 57–58, 90–91, 131–132, 135
 AV access and, 139, 152, 154, 155, 156–159
 delaying dialysis, patient examples, 93–94, 109, 127–128
 delaying dialysis, with electrolyte management, 95–110, **174–176**. *See also* electrolyte management
 dialysis-free years calculation, 90
 early start trend history, 126–129, 132–133
 kidney failure risk equation (KFRE), 91–92

 kidney transplant option versus, 123, 139–140, 141
 kidney transplant timing and, 145–147
 options for, 148–159. *See also* hemodialysis; home dialysis; peritoneal dialysis
 potential harm from, 88–89, 92–94, 128–130, 141
 predicting factors, 62–63, 66, 68, 70, 90–94, 99, 106, **173–174**
 recovery of kidney function during, 57–58, 90–91
 side effects, 129–130
 stages of CKD and, 18, 21, 23
 start guidelines, 4–5, 15, 19–21, 56, 94, 130–136
 statistics on, 1, 66, 68, 69, 70
 summary, 94, 136–137, 160–161, **173–176**, **178–180**, **182–184**
 survival advantage with, 92–94, 128
diclofenac (Voltaren), 82
diuretics
 about, 107
 for congestive heart failure, 62–63, 132
 delaying dialysis and, 107–109
 for high blood pressure, 72, 73–74
 for hyperkalemia, 101
 patient example, 109
 precautions when using, 56, 62–63, 98, 100, 107, 132
 summary, 109–110
Diuril (chlorthalidone), 107. *See also* thiazide diuretics
doxercalciferol (Hectorol), 119. *See also* vitamin D drugs
Dyrenium (triamterene), 100. *See also* potassium-sparing diuretics

E

e-cigarettes, 28
Edecrin (ethacrynic acid), 107. *See also* loop diuretics
eGFR. *See* estimated glomerular filtration rate
electrolyte management, 95–110
 about, 95–96
 alkalosis, 96
 diuretics and, 107–109
 electrolyte, defined, 95
 electrolyte report, defined, 95
 hyperkalemia, 98, 99–106, 135. *See also* hyperkalemia
 continued on next page